Apotex secures an investment-grade issuer rating from Morningstar DBRS and updates its credit facility, enhancing financing flexibility and signaling improved creditworthiness
Executive summary: Apotex announced it received an investment-grade issuer rating from Morningstar DBRS and completed an amended and restated credit agreement. The rating improves Apotex's credit standing, potentially reducing borrowing costs and expanding access to capital.
Who is involved: Apotex Health Corp, Morningstar DBRS, and the company's lending syndicate.
Likely next: Apotex may utilize the updated credit facility for operational needs and could see increased investor interest following the rating.
Apotex Health Corp announced on July 16, 2026 that it has received an investment-grade issuer rating from Morningstar DBRS and simultaneously completed an amended and restated credit agreement. The rating reflects an improved credit profile, while the new credit framework provides the company with additional liquidity and more favorable borrowing terms. Together, these moves strengthen Apotex’s capital structure and may lower its financing costs.
Timeline
- — Apotex Receives Investment Grade Issuer Rating from Morningstar DBRS and Announces Amended & Restated Credit Agreement (PR Newswire)
- — Private credit finds exit opportunities among strategic buyers – DBRS (Yahoo Finance)
Analysis — what this means
Sectors affected
- Generic pharmaceutical manufacturing
Historical parallels
- DBRS rated private credit exit opportunities among strategic buyers – July 10, 2026